Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine

In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed glioblastoma and at the first recurrence. Randomized clinical trials at the second or further recurrence following the failure of radiotherapy, temozolomide and lomustine, and retrospective analyses focusi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncol Lett
Egile Nagusiak: Wenger, Katharina J., Wagner, Marlies, You, Se-Jong, Franz, Kea, Harter, Patrick N., Burger, Michael C., Voss, Martin, Ronellenfitsch, Michael W., Fokas, Emmanouil, Steinbach, Joachim P., Bähr, Oliver
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2017
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494648/
https://ncbi.nlm.nih.gov/pubmed/28693286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6251
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak